Online citations, reference lists, and bibliographies.

The Pharmacology Of Antiulcer Drugs

A. Hurwitz, C. Carter
Published 1989 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The use of medications for the treatment of gastrointestinal ulcers has evolved to a great extent since the early days of therapy with diet and antacids. Today a number of different agents are available to treat the causative factors of ulcer formation. Currently, antacids, histamine2-receptor antagonists, and sucralfate are considered frontline therapies suitable for most patients. The future also looks promising for newer agents, such as omeprazole and prostaglandin analogs. The purpose of this article is to provide practitioners with an understanding of the pharmacology of these agents so that their rational use can be achieved more efficiently and effectively.
This paper references
10.1056/NEJM198504113121505
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.
K. Lauritsen (1985)
Clinical pharmacology: Japanese studies
K OHE (1984)
10.1016/S0016-5085(85)80011-1
Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
K. Mcarthur (1985)
10.1159/000198617
Dynamics of gastric acid inhibition by ranitidine in duodenal ulcer patients.
Stanisław Jan Konturek (1981)
10.5555/uri:pii:0016508578907746
Cimetidine, antacid, and hospitalization in the treatment of benign gastric ulcer: a multicenter double blind study.
E. Englert (1978)
10.1056/NEJM197508212930802
Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.
R. M. Henn (1975)
10.1136/gut.17.3.161
Inhibition of food-stimulated gastric acid secretion by cimetidine.
R. E. Pounder (1976)
10.1001/archinte.1982.00340150073014
Tricyclic antidepressants in the treatment of peptic ulcer disease.
J. C. Mangla (1982)
10.3109/00365528009181452
Inhibition of the histamine-stimulated gastric secretion in healthy subjects by the H2-receptor antagonist ranitidine.
T. Bohman (1980)
10.3109/00365528608996454
Effect of cimetidine on gastric mucosal cell proliferation in man.
Lars Bo Svendsen (1986)
SIMON B . Famotidine ( MK - 208 ) : duration of action , 24 - hour intragastric acidity , antipyrine kinetics and basal hormone levels in man ( abstract )
IT CALLAGHAN (1984)
10.1016/0016-5085(88)90003-0
Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief.
A. Archambault (1988)
10.1007/s40278-018-54876-3
Sucralfate
M. M. Muñóz Navas (1981)
10.1056/NEJM197708182970701
Healing of duodenal ulcer with an antacid regimen.
W. Peterson (1977)
10.1136/bmj.1.5751.709
Acute hypercalcaemia and renal failure after antacid therapy.
D. Malone (1971)
MILTON-THOMPSON GJ,et a1. Effect of cimetidine on 24-hour intragastric acidity in normal subjects
JG POUNDERRE.WILLIAMS (1976)
10.1038/clpt.1985.29
Intravenous nizatidine kinetics and acid suppression
J. T. Callaghan (1985)
10.3109/00365528709078599
Enprostil and cimetidine: comparative efficacy and safety in patients with duodenal ulcer.
L. Carling (1987)
Chronic milk-alkali syndrome associated with prolonged excessive intake of 'Moorland' tablets.
Christopher J. Riley (1970)
10.1159/000182595
The dialysis dementia syndrome and aluminum intoxication.
S. Sideman (1982)
10.1016/0002-9343(85)90566-2
Inhibition of peptic activity by sucralfate.
I. Samloff (1985)
10.2165/00003495-198427030-00002
Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.
R. Brogden (1984)
10.1007/BF01309405
A multicenter international controlled comparison of two dosage regimes of misoprostol and cimetidine in the treatment of duodenal ulcer in out-patients
P. A. Nicholson (1985)
Agents with tricyclic structures for treating peptic ulcer disease.
Rosemary R. Berardi (1983)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
Development and characteristics of sucralfate.
R. Nagashima (1981)
The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion.
R. Sheers (1981)
PAWLIK w. Physiology and pharmacology of prostaglandins
SJ KONTUREK (1986)
10.1056/NEJM198306023082203
Healing of benign gastric ulcer with low-dose antacid or cimetidine. A double-blind, randomized, placebo-controlled trial.
J. Isenberg (1983)
Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
H. Dammann (1986)
10.1056/NEJM198812293192605
The physiology of gastric acid secretion.
M. Wolfe (1988)
mCKSMI. The effect ofcimetidine, a new histamine H2-receptor antagonist on meal-stimulated and secretion serum gastrin, and gastric emptying in patients with duodenal ulcer
JH RICHARDSONcr.WALSH (1976)
fect of ranitidine on gastric and pepsin secretion following sham feeding
RR RYAN (1981)
Sucralfate: a review of drug tolerance and safety.
R. Fisher (1981)
Antacid therapy for duodenal and gastric ulcer: the experience in the United States.
Andrew F. Ippoliti (1982)
Mucosal protective effects of cimetidine
MB KIMMEY (1985)
Double-blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux esophagitis
KLINKENBERG-KNOLEC (1987)
10.1177/1060028087021007-806
Drug-Antacid Interactions: Assessment of Clinical Importance
P. D'Arcy (1987)
Clinical pharmacology of famotidine: summary of data from the United States
RR RYAN (1984)
10.7326/0003-4819-98-1-59
Zollinger-Ellison syndrome: current concepts and management.
R. Jensen (1983)
Antacid side-effects on bowel habits.
M. Ström (1982)
10.1097/00004836-198709011-00005
Sucralfate: worldwide experience in recurrence therapy.
Marks In (1987)
Comparative study with ranitidine and cimetidine on gastric secretion.
K. Fr. Sewing (1981)
WALSH JH . mCKSMI . The effect ofcimetidine , a new histamine H 2 - receptor antagonist on meal - stimulated and secretion serum gastrin , and gastric emptying in patients with duodenal ulcer
T BOHMAN (1976)
10.3109/00365528609091676
Cimetidine and cytoprotection.
R. Cheli (1986)
Cimetidine versus intensive antacid therapy for peptic ulcer disease
AF IPPOUTI (1978)
Effect of 15 R methyl PG~ (arbaprostil) on the healing of duodenal ulcer
G VANfRAPPEN (1982)
10.3109/00365528009181464
Inhibition of gastric secretion in man with a new H2-receptor antagonist, ranitidine.
Kjell Kett (1980)
10.1007/BF01309406
Interim results of a multicenter international comparison of misoprostol and cimetidine in the treatment of out-patients with benign gastric ulcers
M. Shield (1985)
10.1097/00004836-198608000-00005
A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers.
K. Bardhan (1986)
10.1136/gut.24.4.270
Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.
T. Lind (1983)
Famotidine (MK-208): duration of action, 24-hour intragastric acidity, antipyrine kinetics and basal hormone levels in man (abstract)
P MULLER (1984)
10.2165/00003088-197702040-00003
Antacid Therapy and Drug Kinetics
A. Hurwitz (1977)
10.1136/gut.21.3.181
Comparison of ranitidine and cimetidine in the inhibition of histamine, sham-feeding, and meal-induced gastric secretion in duodenal ulcer patients.
S. Konturek (1980)
Omeprazole: a long-acting acid secretion inhibitor
M WEINTRAUB (1988)
Antacids versus placebo in peptic ulcer disease treatment
D HOLLANDER (1973)
10.1056/NEJM197604082941502
Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer.
G. Longstreth (1976)
10.5694/j.1326-5377.1980.tb100771.x
Double-blind trial of trimipramine in the treatment of duodenal ulcer.
G. J. Don (1980)
MCELNAY JC . Drug - antacid interactions : assessment of clinical importance
A BERSTAD (1987)
PHELPS SJ,GREEN BG. Famotidine: a long-acting H2-receptor antagonist. Comparison with cimetidine and ranitidine
JL SMITH (1987)
Mechanisms of action of sucralfate
R. NAGASIllMA (1981)
[Gastric-acid secretion].
M J Varas Lorenzo (1980)
10.3109/00365528609093815
Antacids for peptic ulcer: do we have anything better?
A. Berstad (1986)
Peptic ulcer disease and Zollinger-Ellison syndrome
RR BERARDI (1989)
lnhibition of gastric secretion in man with a new Hrreceptor antagonist , ranitidine
KE SEWING (1980)
motidine : a long - acting H 2 - receptor antagonist . Comparison with cimetidine and ranitidine
JL SMITH (1986)
Duodenal ulcer diseases
MH Sleisenger (1989)
10.1007/BF01296445
Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists
J. Delchier (2005)
Omeprazole orranitidine in the treatment of reflux esophagitis: results of a double-blind randomized Scandinavian multicenter study
SANDMARKS (1988)
10.1136/gut.17.2.133
Effect of cimetidine on 24-hour intragastric acidity in normal subjects.
R. E. Pounder (1976)
10.1136/gut.27.1.106
Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.
I. Hamilton (1986)
10.7326/0003-4819-95-4-535_2
Peptic ulcer : a guide for the practicing physician
M. Grossman (1981)
Effect of ranitidine on gastric acid and pepsin secretion following sham feeding.
S. Müller-lissner (1981)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar